Enterprise Value
1.111B
Cash
351.4M
Avg Qtr Burn
-25.72M
Short % of Float
3.69%
Insider Ownership
7.78%
Institutional Own.
86.49%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
KER-050 Details Blood disorder, Cancer, Myelodysplastic syndrome | Phase 2 Data readout | |
KER-050 Details Lung disease, Myelofibrosis | Phase 2 Data readout | |
KER-047 (ALK2 inhibitor) Details Fibrodysplasia ossificans progressiva, Anemia | Phase 2 Data readout | |
KER-047 (ALK2 inhibitor) Details Myelodysplastic syndrome, Myelofibrosis | Phase 2 Data readout | |
KER-012 Details Pulmonary hypertension, Cardiovascular disease | Phase 2 Initiation |